---
title: "BrightHeart gains US FDA clearance for AI ultrasound software for detecting congenital heart defects"
date: "2024-11-18T10:31:12.000Z"
publishedDate: "18 novembre 2024"
summary: "BrightHeart has received US Food and Drug (FDA) 510(k) clearance for its first artificial intelligence (AI) software, designed to transform prenatal ultrasound evaluations of the foetal heart. Foetal heart ultrasounds exams are essential for detecting congenital heart defects (CHDs), which are the most common type of birth defect, affecting nearly one in 100 newborns."
importance: ""
sourceUrl: "https://cardiovascularnews.com/brightheart-fda-approval/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-11-18-brightheart-gains-us-fda-clearance-for-ai-ultrasound-software-for-detecting-congenital-heart-defects"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/11/BrightHeart_edited.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/brightheart-fda-approval/"
---

![BrightHeart gains US FDA clearance for AI ultrasound software for detecting congenital heart defects](https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/11/BrightHeart_edited.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/brightheart-fda-approval/*

## L’essentiel

BrightHeart has received US Food and Drug (FDA) 510(k) clearance for its first artificial intelligence (AI) software, designed to transform prenatal ultrasound evaluations of the foetal heart. Foetal heart ultrasounds exams are essential for detecting congenital heart defects (CHDs), which are the most common type of birth defect, affecting nearly one in 100 newborns.

## Lien source

https://cardiovascularnews.com/brightheart-fda-approval/
